Showing 5551-5560 of 5621 results for "".
- US Sales of Eylea in First Quarter Best Estimateshttps://modernod.com/news/us-sales-of-eylea-in-first-quarter-best-estimates/2480174/Regeneron Pharmaceuticals reported Thursday that first-quarter sales of Eylea in the US rose 15 percent year-over-year to $984 million, besting analyst estimates of around $922 million. The company’s overall sales increased 15 percent to $1.5 billion, in line with forecasts, as net income s
- ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eyehttps://modernod.com/news/regentree-presents-results-of-a-comparison-study-of-rgn-259-and-approved-prescription-drugs-for-dry-eye-syndrome-in-a-mouse-model-at-arvo/2480176/ReGenTree announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at the ARVO meeting. The study was conducted by Jaewook Yan
- Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC for the Treatment of Glaucomahttps://modernod.com/news/ocular-therapeutix-announces-treatment-of-first-patient-in-phase-1-clinical-trial-of-otx-tic-for-the-treatment-of-glaucoma-and-ocular-hypertension/2480177/Ocular Therapeutix announced the treatment of the first patient in a phase 1, open-label, proof-of-concept clinical trial being conducted in the United States for OTX-TIC, a bioresorbable travoprost implant delivered via an intracameral injection for the reduction of IOP in patients with glaucoma
- Lighthouse Guild Behavioral Programs Focus on the Psychological Impact of Vision Loss, Traumatic Brain Injury and Other Disabilitieshttps://modernod.com/news/lighthouse-guild-behavioral-programs-focus-on-the-psychological-impact-of-vision-loss-traumatic-brain-injury-and-other-disabilities/2480194/For the millions of people who have vision loss, have suffered a traumatic brain injury (TBI), or have developed other physical disabilities due to accident or illness, the psychological impact can be devastating. To meet the needs of these patients, Lighthouse Guild, the leading not-for-profit v
- J&J Vision Introduces Artificial-Intelligence Powered Virtual Assistant for Contact Lenseshttps://modernod.com/news/jj-vision-introduces-artificial-intelligence-powered-virtual-assistant-for-contact-lenses/2480195/Johnson & Johnson Vision introduced Andy, a virtual assistant chatbot powered by artificial intelligence (AI). Andy is designed to help guide U.S. consumers throughout their Acuvue brand contact lens journey – from those considering contact lenses for the first time to long-term wearers. The
- Allergan Presents Data at the ARVO Annual Meeting in Honoluluhttps://modernod.com/news/allergan-presents-data-at-the-arvo-annual-meeting-in-honolulu/2480202/Allergan announced that 19 posters on their eye care offerings will be presented at this year’s ARVO meeting in Hawaii. These presentations will cover a variety of topics in various subspecialties, including ocular surface, glaucoma, and retina. Retina Post
- ARVO 2018: Genentech Ophthalmology Data Highlightshttps://modernod.com/news/arvo-2018-genentech-ophthalmology-data-highlights/2480204/Genentech will be presenting several studies at the Association for Research in Vision and Ophthalmology (ARVO) meeting on April 29 – May 3 in Honolulu. Data being reported at ARVO continue to show the safety and efficacy of Lucentis (ranibizumab) as a treatment for wet age-related macular degene
- Hill-Rom Enhances Spot Vision Screener to Serve Senior Populationhttps://modernod.com/news/hill-rom-enhances-spot-vision-screener-to-serve-senior-population/2480205/Hill-Rom announced new enhancements to its Welch Allyn Spot Vision Screener, enabling the device to quickly and effectively screen for vision issues in adult patients with pupil sizes as small as 3 mm, according to a company news release. Spot Vision Screener is a handheld, portable device
- Blanchard Announces Notching Technology for the Onefit Family of Scleral Lenses: Control Peripheral Recesshttps://modernod.com/news/blanchard-announces-notching-technology-for-the-onefit-family-of-scleral-lenses-control-peripheral-recess/2480206/Blanchard Contact Lenses has unveiled their latest design option for its Onefit and Onefit MED scleral lenses. Control Peripheral Recess (CPR) is a manufacturing process that creates
- Novaliq to Present Scientific and Clinical Research During the 2018 ARVO Meeting in Honoluluhttps://modernod.com/news/novaliq-to-present-scientific-and-clinical-research-during-the-2018-arvo-meeting-in-honolulu/2480208/Novaliq announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) meeting in Honolulu, Hawaii (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With th